AU2019365135B2 - Antibody library and method - Google Patents

Antibody library and method

Info

Publication number
AU2019365135B2
AU2019365135B2 AU2019365135A AU2019365135A AU2019365135B2 AU 2019365135 B2 AU2019365135 B2 AU 2019365135B2 AU 2019365135 A AU2019365135 A AU 2019365135A AU 2019365135 A AU2019365135 A AU 2019365135A AU 2019365135 B2 AU2019365135 B2 AU 2019365135B2
Authority
AU
Australia
Prior art keywords
ala
ser
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019365135A
Other languages
English (en)
Other versions
AU2019365135A1 (en
Inventor
Richard Buick
Natasha CAMPBELL
Darragh MACCANN
James MCCLORY
Leona MCGIRR
Hugh Morgan
Anthony O’KANE
Christopher Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibodies Ltd
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Publication of AU2019365135A1 publication Critical patent/AU2019365135A1/en
Application granted granted Critical
Publication of AU2019365135B2 publication Critical patent/AU2019365135B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019365135A 2018-10-22 2019-10-22 Antibody library and method Active AU2019365135B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1817188.4 2018-10-22
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GB1904754.7 2019-04-04
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
GB1905032.7 2019-04-09
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Publications (2)

Publication Number Publication Date
AU2019365135A1 AU2019365135A1 (en) 2021-05-13
AU2019365135B2 true AU2019365135B2 (en) 2026-08-13

Family

ID=68393020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019365135A Active AU2019365135B2 (en) 2018-10-22 2019-10-22 Antibody library and method

Country Status (10)

Country Link
US (2) US12378696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7853096B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084509A (cg-RX-API-DMAC7.html)
CN (1) CN113195537A (cg-RX-API-DMAC7.html)
AU (1) AU2019365135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115150A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004149A (cg-RX-API-DMAC7.html)
WO (1) WO2020084298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ. ホフマン-ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途
CN121737857A (zh) * 2024-09-26 2026-03-27 上海循曜生物科技有限公司 增强FIX和FIXa活性的纳米抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) * 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016188911A1 (en) * 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292B (zh) * 2018-12-21 2022-11-29 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) * 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOSTROM JENNY, ET AL: "Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 323, no. 5921, 20 March 2009 (2009-03-20), US, pages 1610 - 1614, XP002560553, ISSN: 0036-8075, DOI: 10.1126/science.1165480 *
BRUNO H. MULLER; ALEXANDRA SAVATIER; GUILLAUME L'HOSTIS; NARCISO COSTA; MARC BOSSUS; SANDRINE MICHEL; CATHERINE OTT; LAURENCE: "Affinity Maturation of an Anti-PSA Antibody for Prostate Cancer Diagnostic Assay", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 414, no. 4, 5 October 2011 (2011-10-05), United Kingdom, pages 545 - 562, XP028127019, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2011.10.008 *
YU-CHENG SU, TALAL S AL-QAISI, HSIN-YI TUNG, TIAN-LU CHENG, KUO-HSIANG CHUANG, BING-MAE CHEN, STEVE R ROFFLER: "Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies", MABS, LANDES BIOSCIENCE, US, vol. 6, no. 4, 19 July 2014 (2014-07-19), US, pages 1069 - 1083, XP055299304, ISSN: 1942-0870, DOI: 10.4161/mabs.29124 *

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
US12378696B2 (en) 2025-08-05
JP2022512650A (ja) 2022-02-07
CN113195537A (zh) 2021-07-30
US20210388063A1 (en) 2021-12-16
KR20210084509A (ko) 2021-07-07
BR112021007529A2 (pt) 2021-08-03
JP7853096B2 (ja) 2026-04-28
AU2019365135A1 (en) 2021-05-13
JP2026016427A (ja) 2026-02-03
US20250382726A1 (en) 2025-12-18
MX2021004149A (es) 2021-06-15
EP3870607A1 (en) 2021-09-01
CA3115150A1 (en) 2020-04-30